Lucy Scientific Discovery Inc.
Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant ma… Read more
Lucy Scientific Discovery Inc. (LSDIF) - Net Assets
Latest net assets as of December 2023: $81.16K USD
Based on the latest financial reports, Lucy Scientific Discovery Inc. (LSDIF) has net assets worth $81.16K USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.29 Million) and total liabilities ($4.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $81.16K |
| % of Total Assets | 1.89% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Lucy Scientific Discovery Inc. - Net Assets Trend (2021–2023)
This chart illustrates how Lucy Scientific Discovery Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lucy Scientific Discovery Inc. (2021–2023)
The table below shows the annual net assets of Lucy Scientific Discovery Inc. from 2021 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-06-30 | $4.68 Million | +197.93% |
| 2022-06-30 | $-4.78 Million | +24.83% |
| 2021-06-30 | $-6.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lucy Scientific Discovery Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1484457200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $49.09 Million | 1049.28% |
| Total Equity | $4.68 Million | 100.00% |
Lucy Scientific Discovery Inc. Competitors by Market Cap
The table below lists competitors of Lucy Scientific Discovery Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GLOBE METALS (G4U.SG)
STU:G4U
|
$353.34 |
|
Proton Power Systems PLC
LSE:PPS
|
$353.83 |
|
Rosebank Industries PLC
LSE:ROSE
|
$353.99 |
|
Arab Co. for Asset Management And Development
EGX:ACAMD
|
$354.45 |
|
Zitto Inc
PINK:ZTTO
|
$352.69 |
|
Shires Income
LSE:SHRS
|
$351.43 |
|
TLOU ENERGY LIMITED
XBOT:TLOU-EQO
|
$351.30 |
|
Brøndbyernes IF Fodbold A/S
STU:BYXB
|
$351.05 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lucy Scientific Discovery Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -4,777,950 to 4,678,889, a change of 9,456,839.
- Net loss of 8,988,456 reduced equity.
- New share issuances of 7,500,000 increased equity.
- Other factors increased equity by 10,945,295.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.99 Million | -192.11% |
| Share Issuances | $7.50 Million | +160.29% |
| Other Changes | $10.95 Million | +233.93% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Lucy Scientific Discovery Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | $-4.17 | $0.00 | x |
| 2022-06-30 | $-3.14 | $0.00 | x |
| 2023-06-30 | $2.68 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lucy Scientific Discovery Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -192.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -127532.01%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.88x
- Recent ROE (-192.11%) is below the historical average (-64.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.09 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.38 Million |
| 2023 | -192.11% | -127532.01% | 0.00x | 1.88x | $-9.46 Million |
Industry Comparison
This section compares Lucy Scientific Discovery Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lucy Scientific Discovery Inc. (LSDIF) | $81.16K | 0.00% | 51.82x | $352.93 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |